Saturday 17 October 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
299.77
6.47
−2.11%
Follow CRL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.91 | 2.46 | 2.10 | 2.72 | |
P/FCF ratio |
14.16 | 19.07 | 21.58 | 29.39 | |
P/Operating CF |
36.01 | 67.02 | 205.57 | 60.60 | |
P/B ratio |
2.26 | 3.12 | 2.87 | 3.83 | |
Price to Tangible BV |
0.00 | 150.53 | 0.00 | 0.00 | |
EV/Sales |
2.41 | 2.94 | 2.71 | 3.33 | |
EV/EBITDA |
12.36 | 19.90 | 18.65 | 24.09 | |
EV/Operating CF |
12.92 | 16.01 | 17.99 | 22.88 | |
EV/FCF |
17.81 | 22.78 | 27.90 | 35.94 | |
Quick Ratio |
0.84 | 0.82 | 0.82 | 0.80 | |
Current Ratio |
1.37 | 1.29 | 1.36 | 1.35 | |
Net Debt/EBITDA |
9.04 | (47.87) | 13.21 | 12.97 | |
Debt/Assets |
29.09% | 29.94% | 34.45% | 34.78% | |
Debt/Equity |
0.64 | 0.67 | 0.90 | 0.92 | |
Asset Turnover |
0.52 | 0.55 | 0.53 | 0.53 | |
Operating CF/Net income |
3.93 | (0.53) | (2.77) | (121.27) | |
Capex/Depreciation |
(0.42) | (0.37) | (0.83) | (0.46) | |
Interest Coverage |
5.27 | (11.92) | 4.48 | 3.95 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
17.67% | 19.73% | 16.01% | 22.80% | |
Intangible Assets out of Total Assets |
0.46 | 0.44 | 0.43 | 0.44 | |
Share Based Compensation of Revenue |
2.32% | 1.77% | 2.25% | 1.97% | |
Graham Net Nets |
(0.33) | (0.25) | (0.39) | (0.29) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.99%) | (1.48%) | (2.17%) | (2.13%) | |
Free Cash Flow Yield |
7.06% | 5.24% | 4.63% | 3.40% | |
Revenue per Share |
20.42 | 20.06 | 20.34 | 20.91 | |
Operating CF per Share |
4.34 | 2.98 | 0.84 | 3.74 | |
Capex per Share |
(0.72) | (1.79) | (1.14) | (0.65) | |
Free Cash Flow per Share |
3.62 | 1.18 | (0.30) | 3.09 | |
Cash per Share |
4.21 | 4.31 | 3.92 | 4.00 | |
Shareholders Equity per Share |
69.30 | 63.96 | 60.19 | 59.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
69.30 | 63.96 | 60.19 | 59.27 | |
Free Cash Flow |
178.25 | 58.57 | (14.83) | 148.62 | |
Working Capital |
410.22 | 326.73 | 395.10 | 394.36 | |
Capital Expenditures |
(35.58) | (88.95) | (55.91) | (31.10) | |
Net Current Asset Value |
(2,571.38) | (2,518.44) | (3,295.09) | (3,157.05) | |
EV/EBIT |
68.70 | 469.42 | 155.10 | 147.77 | |
Capex to Sales |
0.04 | 0.09 | 0.06 | 0.03 | |
Price to Operating Income |
54.64 | 392.93 | 119.96 | 120.81 | |
| Other line items | |||||
Average Receivables |
744.34 | 714.89 | 728.44 | 739.66 | |
Average Payables |
152.79 | 144.57 | 141.64 | 143.39 | |
Average Inventory |
319.38 | 288.82 | 324.94 | 312.91 | |
Average Assets |
7,758.83 | 7,331.88 | 7,656.34 | 7,546.35 | |
Average Common Equity |
3,598.73 | 3,318.44 | 3,073.27 | 3,102.81 |
Columns are period end dates